IAG
KLRS

Investmark Advisory Group’s Kalaris Therapeutics KLRS Stock Holding History

Investmark Advisory Group’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-9
Closed -$2K – 372
2021
Q4 		$2K Buy
+9
New +$4.17K ﹤0.01% 359

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Investmark Advisory Group's KLRS Position: Q1 2022 in Review

Investmark Advisory Group sold out of Kalaris Therapeutics (KLRS) in Q1 2022, closing a stake of 9 shares — an estimated $2K sold.

Investmark Advisory Group first reported a position in KLRS in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 84 funds tracked by Wall St. Rank hold KLRS as of Q1 2022.

  • Investmark Advisory Group reported no remaining Kalaris Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Investmark Advisory Group sold 9 Kalaris Therapeutics shares in Q1 2022, an estimated $2K.
  • Investmark Advisory Group first reported a position in Kalaris Therapeutics in Q4 2021 and held it in 1 quarter.
  • Investmark Advisory Group's Kalaris Therapeutics position peaked at $2K in Q4 2021.
  • 84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2022.

Based on Investmark Advisory Group's 13F filing for Q1 2022, filed 3 May 2022.